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Abstract 
Hypertension has high prevalence in the general population, accounts for one in every eight 
consultations in primary care and is a major risk factor for cardiovascular and renal disease. Despite the 
wide availability of suitable medicines, only about 25% of all hypertensive patients have their blood 
pressure controlled adequately. Effective management of patients with hypertension mandates 
assessment for asymptomatic target organ damage and also for potential secondary causes. Accurate 
blood pressure measurement is crucial for diagnosis and may require recordings to be made in the clinic 
and at home, as well as use of ambulatory methods. Treatment is dependent not only on blood pressure 
level but also on total cardiovascular risk. Evidence-based treatment algorithms exist to simplify the 
approach to treatment and most patients require at least two medicines to achieve control. Severely 
elevated blood pressure can lead to acute organ failure that requires emergency treatment but routine 
management of hypertension relies on the careful combination of different classes of drug and titration 
of dosage. 
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Introduction 
Blood pressure (BP) is continuously related to both cardiovascular (CV) diseases and chronic kidney 
disease (CKD) (Figure 1). However, to simplify decisions about diagnosis and pharmacotherapy, 
threshold levels of BP are used in all international guidelines on the management of clinic systolic BP 
(SBP) >140 mmHg and/or diastolic BP (DBP) >90 mmHg1,2 (Table 1). 
 
Epidemiology 
Hypertension is the largest attributable risk factor for mortality worldwide, and is responsible for more 
than half of all stroke and coronary heart disease (CHD). The burden of the problem is increasing, with 
predictions that one-third of adults worldwide will have hypertension by 2025. Despite public health 
programmes and effective pharmacotherapy for hypertension in developed economies, approximately 
25% of adults have hypertension. Hypertension remains untreated in up to 50% of these patients and, 
disappointingly, BP is controlled to guideline-driven targets in only 50% of those hypertensive patients 
advised to take treatment.  
Hypertension is one of the most common chronic non-communicable diseases and accounts for 12% of 
all primary care consultations in UK.1 Blood pressure rises with increasing age and this is thought to 
reflect environmental and lifestyle factors, as well as changes in haemodynamics caused by arterial 
stiffness in the major elastic arterial vasculature, especially the aorta. Increased arterial stiffness causes 
augmentation of SBP and diminution of DBP and is thus also responsible for the increasing prevalence of 
isolated systolic hypertension (ISH) in the elderly. Furthermore, hypertension has a higher prevalence in 
women and ethnic minorities in predominantly Caucasian countries such as the UK and the USA. 
 
Aetiology 
Primary hypertension 
Hypertension is thought to arise from the interplay of multiple genetic traits that are all individually 
responsible for only small increases in BP but collectively may be responsible for 30–50% of individual 
variation, with environmental and lifestyle factors that elevate BP responsible for the rest. Commonly 
implicated medicines/drugs or foodstuffs that elevate BP include non-steroidal anti-inflammatory drugs 
(NSAIDs), steroids, calcineurin inhibitors, hormonal oral contraceptives and female hormone 
replacement, stimulant sympathomimetic medications and illicit drugs, liquorice, salt (sodium chloride) 
and alcohol. Furthermore, a sedentary lifestyle, and dietary patterns of low fruit and vegetable intake, 
as well as high saturated fat and carbohydrate-rich diets that lead to obesity, also contribute to raised 
BP. In such cases where there is no single identifiable cause for hypertension, the term primary 
hypertension is preferred to the historical essential hypertension.. 
 
Secondary hypertension 
In 5–10% of hypertensive patients, an identifiable, possibly reversible or treatable, cause for 
hypertension can be elucidated through careful assessment. These are broadly categorized into renal, 
vascular, endocrine or neural problems (Table 2). In young patients (aged <30 years), patients with 
sudden-onset, severe hypertension, and patients with resistant hypertension (uncontrolled BP despite at 
least three antihypertensive medicines, including a diuretic), the prevalence of secondary causes 
increases to between 20% and 60%.9 The most common secondary causes found in resistant 
hypertension are obstructive sleep apnoea (OSA) (through sympathetic overdrive) and 
hyperaldosteronism (Conn's adenoma or bilateral adrenal hyperplasia causing mineralocorticoid 
excess).9 
 
Diagnosis and evaluation 
Hypertension is normally asymptomatic, though many patients ascribe symptoms such as epistaxis, 
headaches, lethargy and dizziness to their raised blood pressure. Hence, clinical assessment should be 
tailored to answer four key questions: 
•Is the patient truly hypertensive? 
•Is there evidence that hypertension has caused complications (target organ damage (TOD); major CV 
events)? 
•Is a secondary cause identifiable? 
•What is the total CV risk of the patient? 
 
BP measurement 
Blood pressure is an inherently unstable biological variable, subject to seasonal, circadian, hormonal and 
immediate external influences. As such, a single point measure of BP is unlikely to represent usual BP. 
This is particularly important to remember when making a diagnosis or treating a patient for a disease 
that is largely asymptomatic, the purpose of which is to mitigate future CV and renal risk. It is 
established practice to take multiple BP readings at one sitting, and to repeat BP measurement over 
several clinical encounters, to smooth out variation and obtain readings that more closely resemble 
usual BP. 
 
Clinic BP measurement 
Most of our experience in the measurement of BP and the assessment of the beneficial effects of 
treating hypertension relates to recordings made in front of a health professional (clinic BP). 
International guidelines require at least two or three sequential recordings obtained in the non-
dominant arm (unless BP in the dominant arm is greater than 10 mmHg higher than in the non-
dominant) in a seated position after at least 5 minutes rest. Guidelines vary on whether the lowest of 
these readings or the mean of the second and third reading should be used to indicate the true clinic 
BP.1,2  Although traditionally the preferred equipment for BP measurement was the mercury 
auscultatory sphygmomanometer, the withdrawal of mercuric devices from clinical environments has 
led increasingly to the use of validated, semi-automatic, oscillometric devices with appropriately sized 
cuffs, which also allows for the measurement of out-of-office BP (see below). However, these 
oscillometric monitors are not entirely accurate in patients with irregular arrhythmias, such as atrial 
fibrillation, in whom manual aneroid auscultation must be used. A number of cuffless BP monitoring 
devices are on the horizon, and are currently being evaluated in the research setting. Approval of such 
devices for clinical practice will enable collection of high quality longitudinal BP data, and facilitate 
remote patient-clinician telemedicine interactions. 
 
Out-of-office BP measurement 
Out-of-office BP measurement, such as home BP, is particularly useful for the long-term monitoring of 
BP control as it allows multiple recordings to be made between clinic visits. The involvement of patients 
in the management of their disease has benefits for engagement and satisfaction. Furthermore, 
diagnosis of both white-coat hypertension (WCH: high clinic BP, normal out-of-office BP) and masked 
hypertension (normal clinic BP, high out-of-office BP) (Table 1) is very important as these conditions can 
lead to over/under treatment, respectively, and are both associated with increased CV risk compared to 
having normal clinic and out-of-office BP.ii Home BP is usually 5–10 mmHg lower than equivalent clinic 
recordings, though this is exaggerated/reversed in WCH and masked hypertension, respectively. 
As with home BP, ambulatory BP (ABP) monitoring is increasingly used for diagnosis and 
monitoring.1,2  Daytime ABP is 5–10 mmHg lower than clinic BP in the same patient but is superior to 
clinic BP in the determination of CV risk, the ability to rule out WCH in a single event (which may 
represent 10–30% of all hypertensives),ii  the provision of multiple readings to provide improved 
diagnostic accuracy in a single event,12 and the provision of night-time BP (which may suggest OSA if 
there is a failure of BP to dip by 10% below day-time readings).1 Thus, ABP monitoring is mandated by 
latest UK guidelines when making a diagnosis of hypertension.2 However for on-going monitoring, clinic 
BP is considered more appropriate, especially as no major outcome clinical trials have used ABP 
monitoring to guide pharmacotherapy.1 
 
History 
Historical questioning should include childhood illnesses, especially recurrent urinary tract infections, 
and family history, especially of premature vascular disease. In women, evidence of previous pregnancy-
related hypertensive disorders should be specifically sought. 
Dietary assessment is notoriously imprecise but salt intake can be estimated by asking about 
consumption of high-salt containing foodstuffs and whether patients add or cook with salt. Alcohol and 
smoking status should be clarified. Medicines/drugs that interfere with BP (see above) should be asked 
about specifically as should the use of any over-the-counter medicines, herbal or traditional medicines. 
A history of major CV events, such as myocardial infarction, stroke, peripheral arterial disease, 
heart failure and chronic kidney disease should be obtained. Current and previous medication history 
(with intolerances or adverse effects and compliance), length of diagnosis and any self-home BP 
monitoring values should also be collected. Secondary causes may be suggested by abnormal sweating 
(phaeochromocytoma, OSA, acromegaly); palpitations and anxiety (phaeochromocytoma); postural and 
post-prandial symptoms (autonomic dysfunction); or witnessed nocturnal apnoeas and daytime 
somnolence (OSA). 
 
Examination 
Examination should focus on looking for evidence of both asymptomatic TOD and secondary causes. 
TOD can be assessed in three systems: ophthalmic, CV and renal. Direct fundoscopy may reveal different 
grades of hypertensive retinopathy such as silver wiring (grade 1) and arteriovenous nipping (grade 2) 
that represent TOD that is commonly seen in long-standing, poorly controlled hypertension. Flame 
haemorrhages (grade 3) or papilloedema (grade 4) and severe hypertension indicate a diagnosis 
of malignant hypertension mandating immediate anti-hypertensive therapy. Cardiovascular examination 
should include looking for asymptomatic, atherosclerotic arterial disease, such as carotid and femoral 
bruits and abdominal aortic aneurysms. Use of microalbuminuria and proteinuria urine testing strips can 
quickly assess renal TOD at the bedside. 
General appearance may suggest an underlying endocrinopathy (Table 2). Vascular examination 
in a patient with coarctation may reveal disproportionately cool lower limbs with reduced pulses and 
either radio-radial or radio-femoral delay, depending on the exact location of the stenosis. A significant 
coarctation will normally produce a large systolic murmur best heard in the inter-scapular region. Renal 
bruits may signify either atherosclerotic renal artery stenosis or fibromuscular renal artery dysplasia and 
both warrant further investigation. Polycystic kidneys should be easily ballotable in the flanks. 
 
Investigation 
Investigations should be directed towards exploring underlying asymptomatic TOD and secondary 
causes, and to provide a full CV risk profile. All hypertensive patients should be offered. 2 
•Serum electrolytes, estimated glomerular filtration rate (eGFR) and protein:creatinine ratio estimation: 
these will aid detection of asymptomatic chronic kidney disease, and hypokalaemia associated with 
mineralocorticoid (and glucocorticoid) excess may be picked up. 
•Fasting lipids, plasma glucose and glycated haemoglobin: these allow completion of CV-risk estimation 
equations, such as Q-RISK 2.  
•Electrocardiogram (ECG): this will detect electrical left ventricular hypertrophy (LVH), as well as atrial 
fibrillation, which influences selection of the device that can be used to diagnose and monitor BP 
accurately. 
•Transthoracic echocardiography or cardiac magnetic resonance imaging may be used in specialist 
settings to give greater sensitivity and specificity for LVH. 
Other investigations to look for secondary causes will be patient-specific depending on pre-test 
probability from the history and examination, and the necessity/utility of making an underlying 
diagnosis (Table 2). All relatively young patients (aged <40 years) and patients with resistant 
hypertension should be fully evaluated for secondary causes.2 A 24-hour urine collection for electrolytes 
can estimate salt intake. Increasingly, specialists are attempting to determine patient compliance using 
sophisticated tests such as observed tablet taking and subsequent BP measurements, and analytical 
drug (or drug metabolite) assays in urine and plasma.iii Using urine drug-metabolite assays, it has been 
estimated non-adherence is as high as 40% and therefore use of these techniques in routine clinical 
practice may improve identification of true drug-resistant hypertension. 
 
Management 
Hypertension is treated to reduce the risk of major CV and renal events. For this reason, treatment of 
hypertension in isolation from other modifiable CV risk factors (hyperlipidaemia, diabetes, smoking, 
obesity) is inappropriate. CV-risk equations, such as Q-RISK 2 are useful for integrating different risk 
factors, to judge when to treat asymptomatic patients and to provide on-going patient education. 
 
Thresholds and targets 
BP is a continuous variable. CV risk increases in cohort studies at all levels of clinic BP >115/75 
mmHg. However, from intervention trials in uncomplicated hypertension, there is no evidence to 
support antihypertensive treatment in patients with BP <140/90 mmHg.1,2 Indeed, in grade 1 
hypertension, there is scanty evidence that treatment provides a reduction in CV events,1,2 in contrast 
with grade 2 hypertension and above, in which this is well demonstrated. Hence, grade 1 hypertension 
should be treated only if there is concomitant TOD, total CV risk >20% per year2 or highly modifiable 
lifetime risk. In the elderly (aged >80 years), there is even less evidence for treating grade 1 
hypertension, and the biggest study (HYVET)iv aimed for target BP of 150/90 mmHg with large 
reductions in CV morbidity. However, when treating patients with diabetes mellitus with or without 
CKD, or non-diabetic patients with significant proteinuria, one should aim for BP 120–129/<80 mmHg. 
The most recent American guidelines, based on recent meta-analyses and randomised controlled trials, 
have redefined stage 1 hypertension as BP 130-139/80-89mmHg, and stage 2 as BP >140/90mmHg; 
which may pave the way in the future for changes in the threshold for diagnosis in the UK.4 
 
Lifestyle interventions 
All patients should be counselled and supported to introduce and maintain proven lifestyle interventions 
to lower BP and CV risk2 (Table 3):  
 
Pharmacotherapy 
Current UK guidelines are predicated on the use of age and ethnicity as a surrogate for plasma renin 
status: older age (aged >55 years) and African/Caribbean ethnicity are associated with low plasma renin 
activity and are less responsive to angiotensin-converting enzyme inhibition or angiotensin II-receptor 
blockade (Figure 2). Most patients require at least two medicines to control BP1 and it has been 
suggested that pharmacotherapy should start with combination therapy (perhaps in a fixed-dose 
combination single tablet), particularly in those found at the outset to have severe hypertension or 
those with high total CV risk.1 
Resistant hypertension is defined as uncontrolled BP despite maximally tolerated doses of three 
classes of antihypertensive medications including a diuretic (Table 4).2 At this point, it is recommended 
that primary care professionals refer the patient for specialist evaluation of secondary causes and 
treatment. Spironolactone is now the preferred 4th line agent5. 
In contrast to other guidelines, UK NICE guidelines have relegated β-adrenoceptor blockers to 
fifth place,2 unless there is a pressing indication, because of recent meta-analyses suggesting inferior CV 
risk reduction despite similar BP-lowering effects. Medicines from different classes are combined in 
order to target multiple pathophysiological processes (Table 4), A combination of different classes is 
significantly more effective than increasing the dose of a single agent, which increases the risk of 
adverse effects. 
  
Key Points 
 
• Diagnosis of hypertension now requires ABPM or HBPM, as both have been shown to be 
superior to clinic BP in the diagnosis and prognosis of hypertension. Although clinic BP is still 
recommended for monitoring within the clinical setting, engaging patients in HBPM has shown 
to improve patient education and adherence. 
 
• Most patients require a combination of at least two anti-hypertensive medications to reach 
target BP, with American and European guidelines changing to suggest initiation of two classes 
of pharmacotherapy concomitantly at diagnosis 
 
• Patients with uncontrolled hypertension taking step 3 treatment, or young patients with 
hypertension should be referred for expert evaluation 
•  
• Spironolactone is now recommended as the preferred fourth line agent 
  
 
Figure 1 
  
 
Figure 2 
  
 
Definitions and classification of BP levels/patterns by different methods of 
measurement 
 
Category Clinic BP (mmHg) Ambulatory BP (mmHg) 
SBP DBP SBP DBP 
Optimal BP <120 <80 n/a n/a 
Normal BP <130 <85 n/a n/a 
High-normal BP 130–139 85–89 n/a n/a 
Grade 1 hypertension 140–159 90–99 135–149 85–94 
Grade 2 hypertension 160–179 100–109 >150 >95 
Grade 3 hypertension >180 >110 n/a n/a 
Isolated systolic hypertension >140 <90 >135 <85 
White-coat hypertension >140 >90 <135 <85 
Masked hypertension <140 <90 >135 >85 
 
For diagnosis of different grades of hypertension, the highest categorization of DBP or SBP is used. Diagnosis using 
ABPM requires only daytime mean (>14 readings to be valid). Data adapted from Mancia et al.2 and UK NICE 
guidelines.1 BP, blood pressure; DBP, diastolic blood pressure; n/a, not applicable; NICE, National Institute for Health 
and Care Excellence; SBP, systolic blood pressure. 
Table 1  
Common secondary causes of hypertension and their diagnostic tests 
Secondary causes Diagnostic test 
Renal 
Chronic kidney disease (any aetiology) eGFR, P:CR 
Polycystic kidney disease Renal ultrasound 
Reninoma Plasma renin activity 
Page kidney (sub-capsular compression) Renal ultrasound 
Monogenic tubular syndromes (e.g. Liddle's, Gordon's) Serum electrolytes, plasma aldosterone 
Vascular 
Coarctation of aorta CT/MR aorta 
Renovascular diseases 
 
 Atherosclerotic renal stenosis CT/MR renal angiography 
 Fibromuscular dysplasia CT/MR renal angiography 
Endocrine 
Hyperaldosteronism Aldosterone/renin ratio 
Hypercortisolaemia Low-dose dexamethasone suppression 
Phaeochromocytoma Plasma or 24-hour urine metanephrines 
Acromegaly Serum IGF-1, glucose tolerance test 
Hyperthyroidism/hypothyroidism Thyroid function tests 
Disorders of steroid synthesis Measurement of urine steroid precursors 
Neural 
Obstructive sleep apnoea Full polysomnography 
Autonomic failure Autonomic function testing 
Other 
Pregnancy Urine or serum β-HCG 
 
CT, computed tomography; eGFR, estimated glomerular filtration rate; HCG, human chorionic gonadotropin; MR, 
magnetic resonance; P:CR, protein:creatinine ratio. 
Table 2  
Lifestyle interventions  
 
Intervention Approximate SBP reduction 
Regular aerobic exercise (30 minutes/day) 4-9mmHg 
Weight reduction (BMI <25 kg/m2 or waist 
circumference <102cm men, <88cm women) 
5-20mmHg/10kg 
DASH eating plan – increased fruits, vegetables, 
low fat dairy, reduced saturated and total fat intake 
8-14mmHg 
Dietary salt reduction <6g sodium chloride/day 2-8mmHg 
Alcohol (Male < 2units/day, Female <1 unit/day) 2-4mmHg 
 
BMI: Body mass index, 
 
Table 3 
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Antihypertensive medication classes 
 
Class Example Mode of action Duration of 
action 
Adverse effects/monitoring/notes 
ACE-i, 
ARB 
Ramipril, 
Losartan 
Reduce Ang II-
mediated 
vasoconstriction 
Once or 
twice daily 
Reversible renal decline, cough, 
angioedema 
ACE-i contraindicated in bilateral RAS 
CCB 
(DHP) 
Amlodipine Peripheral vasodilator Once daily Peripheral oedema, tachycardia, gum 
hyperplasia 
CCB 
(non-
DHP) 
Diltiazem Peripheral 
vasodilator; 
negatively 
chronotropic 
Once or 
twice daily 
as MR 
formulation 
Peripheral oedema, bradycardia, 
constipation. Do not co-prescribe with β-
blocker 
Diuretic 
(Th-L) 
Indapamide Vasodilator and 
salt/water excretion 
Once daily Hypokalaemia/hyponatraemia, 
hyperuricaemia, glucose. Avoid nocturnal 
dosing 
MRA Spironolactone Salt/water excretion Once daily Hyperkalaemia, painful gynaecomastia 
Avoid if eGFR <30 mL/min 
β-
Blocker 
Atenolol Inhibit renin 
secretion; negatively 
inotropic/chronotropic 
Once daily Bradycardia, bronchospasm, disturbed 
sleep, lethargy. Do not co-prescribe with 
non-DHP CCB 
α-
Blocker 
Doxazosin Peripheral vasodilator Twice daily Postural hypotension, urge incontinence, 
peripheral oedema 
Central 
agent 
Clonidine Reduce central 
sympathetic outflow 
Three times 
daily 
Dry mouth, disturbed sleep, sedation 
Be wary of rebound hypertension at end of 
use 
 
Different classes of medicines used for hypertension and their mode of action, important and common adverse effects, monitoring 
requirements. For a comprehensive list of significant medicine–medicine interactions, please consult the British National 
Formulary. ACE-I, angiotensin-converting enzyme inhibitor; Ang II, angiotensin II; ARB, angiotensin-receptor blocker; CCB, calcium-
channel blocker; DHP, dihydropyridine; eGFR, estimated glomerular filtration rate; M/R, modified-release; MRA, mineralocorticoid 
receptor antagonist; RAS, renal artery stenosis; Th-L, thiazide-like diuretic. 
Table 4  
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Self Assessment Questions 
  
Question 1: 
A 64-year-old asymptomatic Caucasian gentleman with a background of well-controlled Type II diabetes 
mellitus continues to have uncontrolled blood pressure (clinic BP 155/97mmHg, HBPM 148/92mmHg). 
His current medication includes Ramipril 10mg daily, Amlodipine 10mg daily, Indapamide M/R 1.5mg 
daily, for which he ensures compliance. His most recent blood tests results are – Na+142 mmol/L, K+-3.9 
mmol/L, eGFR 72ml/min/1.73m2. 
 
In addition to emphasizing lifestyle management advice, which of the following management steps is 
most appropriate? 
a. Increase to Ramipril 10mg twice daily 
b. Review BP in 6 months 
c. Start atenolol 50mg daily 
d. Commence spironolactone 25mg daily 
e. Refer to cardiologist 
 
Explanation  
This gentleman is currently above his BP treatment target; 50% of patients with hypertension are 
inadequately treated and do not achieve target BP. In addition to lifestyle interventions, a fourth line 
drug should be added straight away given that delay in treating is associated with increased risk of CV 
events. Spironolactone has been proven to be superior to non-diuretic add on drugs at lowering blood 
pressure and is therefore is now the preferred 4th line agent. Monitoring of his renal function will be 
required. 
NICE does recommend referral to a hypertension specialist in if BP uncontrolled on 3 drugs (resistant 
hypertension) – a list of hypertension specialist referral centres is available on the website of the British 
& Irish Hypertension Society: https://bihsoc.org/referral-centres/ 
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Question 2: 
A 93-year-old asymptomatic lady with a background of osteoarthritis, macular degeneration and 
irritable bowel syndrome attends clinic with a  BP of 148/80mmHg, and domiciliary BP measurements 
with a validated device are on average less than this. Her current antihypertensive prescription is for 
ramipril 10mg daily and felodipine 10mg daily and she assures you that she is fully adherent with her 
medication. Her renal function results are:  Na+139 mmol/L, K+-4.1 mmol/L, eGFR 50 ml/min/1.73m2. 
 
In addition to lifestyle recommendations,, which of the following options should be taken in regard with 
her pharmacotherapy? 
a. No changes in medication 
b. Initiate indapamide M/R 1.5mg daily 
c. Start doxazosin 4mg twice daily 
d. Commence spironolactone 25mg daily 
e. Refer for ABPM 
 
Explanation 
The current evidence base recommends treatment of patients above the age of 80 years to a systolic BP 
target of < 150mmHg and therefore no further changes in medication are required. Given that she is 
already on an ACE-I and a CCB, the next drug choice would therefore be indapamide (b), as per the 
treatment algorithm (figure 2) if the BP control was to deteriorate to levels above target. 
 
 
  
Question 3:  
A 27-year-old female primary school teacher is referred to the ambulatory clinic with hypertension 
(182/102mmHg), blurred vision and headaches. She has recently been treated for a urinary tract 
infection with several courses of antibiotics, and visited the GP in the last 3 months for generalized 
weakness. She has a family history of hypertension and takes no regular medication. Her renal function 
results are: Na+143 mmol/L, K+-2.9 mmol/L, eGFR 90ml/min/1.73m2. 
 
What would be the investigation of choice in this patient? 
a. Aldosterone/Renin assay once potassium levels normalised 
b. Low dose dexamethasone suppression test 
c. CT angiography of the renal arteries 
d. Urine βHCG 
e. ABPM 
 
Explanation 
Her symptoms, hypokalaemia and positive family history all point to a diagnosis of primary 
hyperaldosteronism; for which the initial investigation is aldosterone/renin ratio and would 
demonstrate high aldosterone levels with suppressed plasma renin activity and thus a very high ratio. B 
is used to diagnose hypercortisolaemia once elevated cortisol excretion is demonstrated. CT 
angiography is indicated if a diagnosis of renal artery stenosis or fibromuscular dysplasia is suggested in 
the history/examination or if other secondary causes of hypertension are excluded. A CT scan of the 
adrenal glands will be necessary following a positive finding of A. Although pregnancy is common in this 
age group, and should always be tested for in women of childbearing age, her presentation and positive 
family history make this less likely.  
